Form 4: Clover Health CEO Sells 175,000 Shares Under 10b5-1 Plan

Clover Health's CEO of Home Care, Brady Priest, reported the sale of 175,000 Class A Common Stock shares for $2.17 per share.

Summary

• Brady Patrick Priest, CEO of Home Care at Clover Health Investments, Corp. (CLOV), sold 175,000 shares of Class A Common Stock.
• The transaction occurred on March 4, 2026, at a weighted average price of $2.17 per share.
• The shares were sold in multiple transactions at prices ranging from $2.16 to $2.18, inclusive.
• Following this sale, Priest beneficially owns 1,998,584 shares of Class A Common Stock.
• The transaction was made pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal due to a significant insider sale, despite being executed under a 10b5-1 plan, which typically reduces the perceived urgency or opportunistic nature of the sale.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, which indicates a pre-scheduled sale and can mitigate concerns about opportunistic insider selling.

Negatives

• An insider, specifically the CEO of Home Care, sold a significant number of shares (175,000), which can be interpreted as a negative signal regarding management's confidence in the company's near-term prospects.
• The sale price of $2.17 per share is relatively low, potentially indicating a lack of belief in substantial short-term price appreciation.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider sales, even those conducted under a 10b5-1 plan, are often scrutinized by the market as they can signal a lack of conviction from management, especially in the healthcare technology sector where growth prospects and competitive landscapes are constantly evolving.

Comparison to Industry Standards

• Insider sales are common across all industries. While a 10b5-1 plan suggests a pre-planned divestment rather than an immediate reaction to new information, the sale of 175,000 shares by a CEO-level executive is a notable event.
• Similar sales by executives at other health tech companies like Teladoc Health or Amwell would typically draw investor attention, particularly if the company's stock has been under pressure or if there are no clear reasons for the sale (e.g., tax planning, diversification).
• The volume of shares sold represents a significant portion of the executive's holdings, though the remaining 1.99 million shares still represent substantial ownership.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal, potentially leading to downward pressure on the stock price.
• Management and employees could potentially experience an impact on morale if interpreted as a lack of confidence from leadership, though a 10b5-1 plan often mitigates this.

Key Dates

Recommendation

While the insider sale is a negative signal, the transaction was pre-planned under a 10b5-1 plan, which lessens the immediate negative impact compared to an unplanned sale. The remaining beneficial ownership is still substantial. Investors should hold and monitor future company performance and additional insider activity rather than making an immediate sell decision based solely on this Form 4.

Keywords

Clover Health, CLOV, insider trading, Form 4, stock sale, Brady Priest, CEO Home Care, 10b5-1 plan, beneficial ownership